Chronic Obstructive Pulmonary Disease (COPD)ACCEPT-TRNCT07747571
Factors Associated With Acceptance of Home-Based Pulmonary Telerehabilitation in COPD
An observational study of Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Rehabilitation, run by ADIR Association at 1 site in France.
Trial summary
Pulmonary rehabilitation improves symptoms, exercise capacity, and quality of life in people with chronic obstructive pulmonary disease (COPD), but access and participation may be limited by travel, organizational, logistical, and personal barriers. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Rehabilitation
- How many people
- 50 participants
- Where
- 1 siteFrance
- Study dates
- 1 Sep 2026to 31 Oct 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults with COPD who were screened at ADIR Association between May 2024 and April 2025 for an 8-week home-based pulmonary telerehabilitation feasibility study.
Who may be able to join
- Adults with COPD who were screened at ADIR Association between May 2024 and April 2025 for an 8-week home-based pulmonary telerehabilitation feasibility study. Please refer to ClinicalTrials.gov identifier NCT05314686.
Who cannot join
- Not applicable
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
ADIR Association
Rouen, Normandy, 76000
Tristan Bonnevie, PhD, +33235592970, t.bonnevie@adir-hautnormandie.com
Tristan Bonnevie, PhD
About this study
Official title: Factors Associated With Acceptance or Refusal of Participation in a Home-Based Pulmonary Telerehabilitation Program Among Adults With Chronic Obstructive Pulmonary Disease: A Retrospective Study
Pulmonary rehabilitation improves symptoms, exercise capacity, and quality of life in people with chronic obstructive pulmonary disease (COPD), but access and participation may be limited by travel, organizational, logistical, and personal barriers. Home-based pulmonary telerehabilitation may reduce some of these barriers, although not all eligible individuals accept this mode of care. Identifying the characteristics associated with acceptance or refusal of this model is therefore essential to better define the population most likely to benefit from this approach, tailor the program's delivery and content, and identify potential remaining barriers in order to improve access to care.
This retrospective study will use existing data from adults with COPD who were screened at ADIR Association between May 2024 and April 2025 for an 8-week home-based pulmonary telerehabilitation feasibility study. Of 50 potentially eligible individuals, 21 accepted participation and 29 declined. Demographic, clinical, functional, psychological, and geographic characteristics will be compared between individuals who accepted and those who declined participation. Documented reasons for refusal will be described, and factors associated with refusal will be explored using logistic regression.
Read the detailed description
ACCEPT-TELEREHAB is a single-center retrospective observational cohort study based on data collected during screening for the TELEREHAPP feasibility study (ClinicalTrials.gov identifier NCT05314686). The source cohort comprises all individuals with COPD who were screened and considered potentially eligible for an 8-week home-based pulmonary telerehabilitation program at ADIR Association between May 2024 and April 2025. Participants will be classified according to the decision recorded at screening: acceptance or refusal of the proposed telerehabilitation program.
Data will be extracted from the original screening file, medical records, and information available from the pulmonary rehabilitation referral and assessment. Variables of interest include age, sex, body mass index, COPD severity, comorbidities, available pulmonary function and exercise-test data, long-term oxygen therapy, dyspnea, quality of life, psychological status, functional exercise capacity, previous pulmonary rehabilitation, and the setting of any previous pulmonary rehabilitation program. When a reason for declining participation was documented, it will be coded retrospectively into descriptive categories; more than one category may be assigned to a single participant.
Home-to-center distance and estimated travel time will be derived using a standardized mapping procedure. The residential address available at screening will be used to calculate the fastest car journey to ADIR Association for a standardized arrival time of 9:00 AM on a working Tuesday outside public holidays and school vacations.
Continuous variables will be summarized using means and standard deviations or medians and interquartile ranges, as appropriate. The acceptance and refusal groups will be compared using independent-samples t tests or Wilcoxon-Mann-Whitney tests for continuous variables and chi-square or Fisher exact tests for categorical variables. Differences will be reported with 95% confidence intervals. Refusal to participate will be the dependent variable in univariable and multivariable logistic regression models. Results will be reported as odds ratios with 95% confidence intervals.
- Being tested
- No intervention
- Keywords
- Telerehabilitation, Home-based pulmonary rehabilitation, Patient preference, Access to care
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive, Patient Preference
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No interventionOther
None for the present retrospective study.
| Study group | Role | What they receive |
|---|---|---|
| Group 1: Accepted Home-Based Pulmonary Telerehabilitation | Individuals who accepted participation in the original 8-week home-based pulmonary telerehabilitation feasibility study and were enrolled in that study. Expected source count: 21. Receives: Other: No intervention | |
| Group 2: Declined Home-Based Pulmonary Telerehabilitation | Individuals who were screened and considered potentially eligible for the original feasibility study but declined participation in the proposed home-based pulmonary telerehabilitation program. Expected source count: 29. Receives: Other: No intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Participation Decision Regarding Home-Based Pulmonary Telerehabilitation
The participation decision recorded at screening will be classified as acceptance or refusal of the proposed 8-week home-based pulmonary telerehabilitation program. The number and percentage of participants in each category will be reported.
Measured: At screening, before initiation of the proposed 8-week telerehabilitation program
Secondary outcomes (25)
Documented Reasons for Refusal of Home-Based Pulmonary Telerehabilitation
Reasons for refusal documented in the screening file or medical record will be coded retrospectively into descriptive categories and reported as numbers and percentages among participants with an available reason. More than one category may be assigned to a participant.
Measured: At screening, when the participation decision was documented
Distance From the Participant's Residence to the Pulmonary Rehabilitation Center
Distance from the residence recorded at screening to ADIR Association will be calculated using a standardized mapping procedure and expressed in kilometers. The derived value will be compared between participants who accepted and declined telerehabilitation.
Measured: At the time of screening
Estimated Travel Time From the Participant Residence to the Pulmonary Rehabilitation Center
The estimated duration of the fastest car journey from the residence recorded at screening to ADIR Association will be calculated using a standardized mapping procedure and expressed in minutes. The derived value will be compared between participation-decision groups.
Measured: At the time of screening
Age At Screening
Age in years at screening will be compared between participants who accepted and declined telerehabilitation.
Measured: At the time of screening
Sex Distribution
The number and percentage of female and male participants will be reported for each participation-decision group.
Measured: At the time of screening
Body Mass Index At Screening
Body mass index will be calculated as weight in kilograms divided by height in meters squared and compared between groups.
Measured: At the time of screening
Chronic Obstructive Pulmonary Disease Severity
COPD severity available in the medical record, including Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric grade when documented, will be reported by participation-decision group.
Measured: At the time of screening
Long-term oxygen Status
The number and percentage of participants receiving long-term oxygen therapy will be reported for each group.
Measured: At the time of screening
Modified Medical Research Council Dyspnea Scale Score
Functional dyspnea will be assessed using the modified Medical Research Council (mMRC) dyspnea scale. Scores range from 0 to 4, with higher scores indicating greater dyspnea-related disability.
Measured: At the time of screening
Visual Simplified Respiratory Questionnaire Score
Respiratory quality of life will be assessed using the Visual Simplified Respiratory Questionnaire (VSRQ). Scores range from 0 to 80, with higher scores indicating better respiratory quality of life.
Measured: At the time of screening
Saint George's Respiratory Questionnaire
Respiratory quality of life will be assessed using the Saint George's Respiratory Questionnaire (SGRQ). Scores range from 0 to 100, with lower scores indicating better respiratory quality of life.
Measured: At the time of screening
Hospital Anxiety and Depression Scale Anxiety Subscale Score
Anxiety symptoms will be assessed using the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). Scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms.
Measured: At the time of screening
Hospital Anxiety and Depression Scale Depression Subscale Score
Depressive symptoms will be assessed using the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D). Scores range from 0 to 21, with higher scores indicating more severe depressive symptoms.
Measured: At the time of screening
Six-Minute Walk Distance
Functional exercise capacity will be expressed as the distance walked during the 6-minute walk test, in meters.
Measured: At the time of screening
Six-Minute Stepper Test Performance
Functional exercise capacity will be expressed as the number of steps completed during the 6-minute stepper test.
Measured: At the time of screening
One-Minute Sit-to-Stand Test Performance
Functional exercise capacity will be expressed as the number of complete repetitions performed during the 1-minute sit-to-stand test.
Measured: At the time of screening
Peak Oxygen Uptake During Cardiopulmonary Exercise Testing
Peak oxygen uptake (VO2peak), when available, will be extracted from the most recent cardiopulmonary exercise test and compared between groups.
Measured: At the time of screening
Previous Participation in Pulmonary Rehabilitation
The number and percentage of participants who had previously participated in a pulmonary rehabilitation program will be reported for each group.
Measured: At the time of screening
Setting of Previous Pulmonary Rehabilitation
When available, the setting of previous pulmonary rehabilitation will be classified as center-based, home-based, telerehabilitation, private physiotherapy practice, hybrid or mixed, other, or unknown.
Measured: At the time of screening
Pulmonary Function at Screening - Forced Expiratory Volume in 1 Second
The most recent forced expiratory volume in 1 second (FEV1) available at the time of screening for the initial telerehabilitation study will be extracted from the medical record. FEV1 will be reported as an absolute volume in liters and as a percentage of the predicted value. Values will be compared between participants who accepted and those who declined participation in the home-based pulmonary telerehabilitation program.
Measured: At the time of screening
Pulmonary Function at Screening - Forced Vital Capacity
The most recent forced vital capacity (FVC) available at the time of screening for the initial telerehabilitation study will be extracted from the medical record. FVC will be reported as an absolute volume in liters and as a percentage of the predicted value. Values will be compared between participants who accepted and those who declined participation in the home-based pulmonary telerehabilitation program.
Measured: At the time of screening
Pulmonary Function at Screening - FEV1/FVC Ratio
The most recent ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) available at the time of screening for the initial telerehabilitation study will be extracted from the medical record. The FEV1/FVC ratio will be reported as a percentage. Values will be compared between participants who accepted and those who declined participation in the home-based pulmonary telerehabilitation program.
Measured: At the time of screening
Pulmonary Function at Screening - Residual Volume
The most recent residual volume (RV) available at the time of screening for the initial telerehabilitation study will be extracted from the medical record. RV will be reported as an absolute volume in liters and as a percentage of the predicted value. Values will be compared between participants who accepted and those who declined participation in the home-based pulmonary telerehabilitation program.
Measured: At the time of screening
Pulmonary Function at Screening - Total Lung Capacity
The most recent total lung capacity (TLC) available at the time of screening for the initial telerehabilitation study will be extracted from the medical record. TLC will be reported as an absolute volume in liters and as a percentage of the predicted value. Values will be compared between participants who accepted and those who declined participation in the home-based pulmonary telerehabilitation program.
Measured: At the time of screening
Pulmonary Function at Screening - Slow Vital Capacity
The most recent slow vital capacity (VC) available at the time of screening for the initial telerehabilitation study will be extracted from the medical record. VC will be reported as an absolute volume in liters and as a percentage of the predicted value. Values will be compared between participants who accepted and those who declined participation in the home-based pulmonary telerehabilitation program.
Measured: At the time of screening
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Aug 2026
- Study start1 Sep 2026 (estimated)
- Primary completion31 Oct 2026 (estimated)
- Study completion31 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Obstructive Pulmonary Disease (COPD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- ADIR Association
- Sponsor type
- University, hospital or other
- Collaborators
- University of Rouen Normandie, Hopital La Musse
- Responsible party
- Sponsor
- Investigators
- Tristan Bonnevie, PhD, Principal investigator, ADIR Association
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07747571
- Sponsor's protocol ID
- ACCEPT-TELEREHAB
- Acronym
- ACCEPT-TR
- Status last verified
- Jul 2026
- First submitted
- 31 Jul 2026
- Last updated
- 10 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data will be made available upon reasonable request for research purposes after publication. This includes de-identified data related to demographic characteristics, as well as endpoints published either in the main manuscript or any supplemental data. Requests should be sent to t.bonnevie@adirhautenormandie.com
Study at a glance
From the registry record, last updated by the sponsor on 10 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Factors Associated With Acceptance or Refusal of Participation in a Home-Based Pulmonary Telerehabilitation Program Among Adults With Chronic Obstructive Pulmonary Disease: A Retrospective Study
- ClinicalTrials.gov ID
- NCT07747571
- Acronym / sponsor ID
- ACCEPT-TR / ACCEPT-TELEREHAB
- Keywords
- Telerehabilitation, Home-based pulmonary rehabilitation, Patient preference, Access to care
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- ADIR AssociationUniversity, hospital or other
- Collaborators
- University of Rouen Normandie, Hopital La Musse
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 31 Oct 2026 (estimated)
- Study completion
- 31 Oct 2026 (estimated)
- First posted
- 5 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pulmonary rehabilitation improves symptoms, exercise capacity, and quality of life in people with chronic obstructive pulmonary disease (COPD), but access and participation may be limited by travel, organizational, logistical, and personal barriers. Home-based pulmonary telerehabilitation may reduce some of these barriers, although not all eligible individuals accept this mode of care. Identifying the characteristics associated with acceptance or refusal of this model is therefore essential to better define the population most likely to benefit from this approach, tailor the program's delivery and content, and identify potential remaining barriers in order to improve access to care.
This retrospective study will use existing data from adults with COPD who were screened at ADIR Association between May 2024 and April 2025 for an 8-week home-based pulmonary telerehabilitation feasibility study. Of 50 potentially eligible individuals, 21 accepted participation and 29 declined. Demographic, clinical, functional, psychological, and geographic characteristics will be compared between individuals who accepted and those who declined participation. Documented reasons for refusal will be described, and factors associated with refusal will be explored using logistic regression.
Detailed description
ACCEPT-TELEREHAB is a single-center retrospective observational cohort study based on data collected during screening for the TELEREHAPP feasibility study (ClinicalTrials.gov identifier NCT05314686). The source cohort comprises all individuals with COPD who were screened and considered potentially eligible for an 8-week home-based pulmonary telerehabilitation program at ADIR Association between May 2024 and April 2025. Participants will be classified according to the decision recorded at screening: acceptance or refusal of the proposed telerehabilitation program.
Data will be extracted from the original screening file, medical records, and information available from the pulmonary rehabilitation referral and assessment. Variables of interest include age, sex, body mass index, COPD severity, comorbidities, available pulmonary function and exercise-test data, long-term oxygen therapy, dyspnea, quality of life, psychological status, functional exercise capacity, previous pulmonary rehabilitation, and the setting of any previous pulmonary rehabilitation program. When a reason for declining participation was documented, it will be coded retrospectively into descriptive categories; more than one category may be assigned to a single participant.
Home-to-center distance and estimated travel time will be derived using a standardized mapping procedure. The residential address available at screening will be used to calculate the fastest car journey to ADIR Association for a standardized arrival time of 9:00 AM on a working Tuesday outside public holidays and school vacations.
Continuous variables will be summarized using means and standard deviations or medians and interquartile ranges, as appropriate. The acceptance and refusal groups will be compared using independent-samples t tests or Wilcoxon-Mann-Whitney tests for continuous variables and chi-square or Fisher exact tests for categorical variables. Differences will be reported with 95% confidence intervals. Refusal to participate will be the dependent variable in univariable and multivariable logistic regression models. Results will be reported as odds ratios with 95% confidence intervals.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1: Accepted Home-Based Pulmonary Telerehabilitation | – | Other: No interventionIndividuals who accepted participation in the original 8-week home-based pulmonary telerehabilitation feasibility study and were enrolled in that study. Expected source count: 21. |
| Group 2: Declined Home-Based Pulmonary Telerehabilitation | – | Other: No interventionIndividuals who were screened and considered potentially eligible for the original feasibility study but declined participation in the proposed home-based pulmonary telerehabilitation program. Expected source count: 29. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults with COPD who were screened at ADIR Association between May 2024 and April 2025 for an 8-week home-based pulmonary telerehabilitation feasibility study.
Key inclusion criteria (1 listed)
- Adults with COPD who were screened at ADIR Association between May 2024 and April 2025 for an 8-week home-based pulmonary telerehabilitation feasibility study. Please refer to ClinicalTrials.gov identifier NCT05314686.
Key exclusion criteria (1 listed)
- Not applicable
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No interventionNone for the present retrospective study. | Other | Group 1: Accepted Home-Based Pulmonary Telerehabilitation, Group 2: Declined Home-Based Pulmonary Telerehabilitation |
Primary outcome
Participation Decision Regarding Home-Based Pulmonary Telerehabilitation
Time frame: At screening, before initiation of the proposed 8-week telerehabilitation program
The participation decision recorded at screening will be classified as acceptance or refusal of the proposed 8-week home-based pulmonary telerehabilitation program. The number and percentage of participants in each category will be reported.
25 secondary outcomes
Documented Reasons for Refusal of Home-Based Pulmonary Telerehabilitation
Time frame: At screening, when the participation decision was documented
Distance From the Participant's Residence to the Pulmonary Rehabilitation Center
Time frame: At the time of screening
Estimated Travel Time From the Participant Residence to the Pulmonary Rehabilitation Center
Time frame: At the time of screening
Age At Screening
Time frame: At the time of screening
Sex Distribution
Time frame: At the time of screening
Body Mass Index At Screening
Time frame: At the time of screening
Chronic Obstructive Pulmonary Disease Severity
Time frame: At the time of screening
Long-term oxygen Status
Time frame: At the time of screening
Modified Medical Research Council Dyspnea Scale Score
Time frame: At the time of screening
Visual Simplified Respiratory Questionnaire Score
Time frame: At the time of screening
Saint George's Respiratory Questionnaire
Time frame: At the time of screening
Hospital Anxiety and Depression Scale Anxiety Subscale Score
Time frame: At the time of screening
Hospital Anxiety and Depression Scale Depression Subscale Score
Time frame: At the time of screening
Six-Minute Walk Distance
Time frame: At the time of screening
Six-Minute Stepper Test Performance
Time frame: At the time of screening
One-Minute Sit-to-Stand Test Performance
Time frame: At the time of screening
Peak Oxygen Uptake During Cardiopulmonary Exercise Testing
Time frame: At the time of screening
Previous Participation in Pulmonary Rehabilitation
Time frame: At the time of screening
Setting of Previous Pulmonary Rehabilitation
Time frame: At the time of screening
Pulmonary Function at Screening - Forced Expiratory Volume in 1 Second
Time frame: At the time of screening
Pulmonary Function at Screening - Forced Vital Capacity
Time frame: At the time of screening
Pulmonary Function at Screening - FEV1/FVC Ratio
Time frame: At the time of screening
Pulmonary Function at Screening - Residual Volume
Time frame: At the time of screening
Pulmonary Function at Screening - Total Lung Capacity
Time frame: At the time of screening
Pulmonary Function at Screening - Slow Vital Capacity
Time frame: At the time of screening
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2026.
- Individual participant dataSharing planned: Yes. Data will be made available upon reasonable request for research purposes after publication. This includes de-identified data related to demographic characteristics, as well as endpoints published either in the main manuscript or any supplemental data. Requests should be sent to t.bonnevie@adirhautenormandie.com
Related trials for Chronic Obstructive Pulmonary Disease (COPD)
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Active, not recruitingPhase 1
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Tristan Bonnevie, PhD principal investigator
ADIR Association
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Rehabilitation, run by ADIR Association at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tristan Bonnevie, PhD (+33235592970, t.bonnevie@adir-hautenormandie.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Participation Decision Regarding Home-Based Pulmonary Telerehabilitation (time frame: At screening, before initiation of the proposed 8-week telerehabilitation program). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026.